Evaluation of prescription practices of long acting injectable risperidone in French hospitals;Enquête des prescriptions de rispéridone injectable libération prolongée dans neuf centres hospitaliers du réseau PIC

Encephale

Volumn 37, Issue SUPPL. 1, 2011, Pages

  Bret, P ^a   Heil, M ^a   Queuille, E ^a   Bret, M C ^a  

^a Service Pharmacie   (France)

Author keywords

Atypical antipsychotics; Collaborative Working Group from the PIC network; Long acting injectable risperidone; Observational study; Prescribing practices

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LONG ACTING DRUG; LONG ACTING INJECTABLE RISPERIDONE; NEUROLEPTIC AGENT; RISPERIDONE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FRANCE; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PROFESSIONAL PRACTICE; PROFESSIONAL STANDARD; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIPOLAR DISORDER; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PATIENT DROPOUTS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RISPERIDONE; YOUNG ADULT;

EID: 79956205036     PISSN: 00137006     EISSN: 00137006     Source Type: Journal    
DOI: 10.1016/j.encep.2010.04.001     Document Type: Article

References (10)

1. Y.M. Bai, Chen Tt, and J.Y. Chen Equivalent switching dose from oral risperidone to risperidon long-acting injection: a 48-week randomised, prospective, single blind pharmacokinetic study J Clin Psychiatry 68 2007 1218 1225 (Pubitemid 47395624)
2. M. Eerdekens, I. Van Hove, and B. Remmerie Phamacokinetics and tolerability of long acting risperidone in schizophrenia Schizophr Res 70 2004 91 100 (Pubitemid 38916632)
3. W.W. Fleischhacker, M. Eerdekens, and K. Karcher Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic J Clin Psychiatry 64 2003 1250 1257
4. J.M. Kane, M. Eederkens, and J.P. Lindenmayer Long acting injectable risperidone: efficacy and safety of the first long acting atypical antipsychotic Am J Psychiatry 160 2003 1125 1132 (Pubitemid 41070972)
5. R.A. Lasser, C.A. Bossie, and G.M. Gharabawi Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long acting risperidone Eur Psychiatry 19 2004 219 225 (Pubitemid 38766136)
6. R.A. Lasser, C.A. Bossie, and G.M. Gharabawi Clinical improvement in 336 stable chronically psychotic patients changed from oral to long acting: a 12 month open trial Int J Neuropsychopharmacol 8 2005 427 438 (Pubitemid 41002496)
7. J.P. Lindenmayer, E. Eederkens, and S.A. Berry Safety and efficacy of long acting risperidone in schizophrenia: a 12-week, multi center, open-label study in stable patients switched from typical and atypical oral antipsychotics J Clin Psychiatry 65 2004 1084 1089
8. H.J. Moller, P.M. Llorca, and E. Sacchetti Efficacy and safety of direct transition to risperidone long acting injectable in patients treated with various antipsychotics therapies Int Clin Psychopharmacol 20 2005 121 130 (Pubitemid 40571509)
9. C. Raignoux, T. Dusouchet, and P. Bret La rispéridone injectable libération prolongée : enquête d'utilisation dans trois établissements d'Aquitaine Encéphale 33 2007 973 981 (Pubitemid 351635744)
10. G.M. Simpson, R.A. Mahmoud, and R.A. Lasser A 1 year double bind study of 2 doses of long acting risperidone in stable patients with schizophrenia or schizoaffective disorder J Clin Psychiatry 67 2006 1194 1203 (Pubitemid 44439690)